Babiker H - Search Results

1

Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates.

Arvind R, Chandana SR, Borad MJ, Pennington D, Mody K, Babiker H. Arvind R, et al. Among authors: babiker h. Crit Rev Oncol Hematol. 2021 Dec;168:103535. doi: 10.1016/j.critrevonc.2021.103535. Epub 2021 Nov 19. Crit Rev Oncol Hematol. 2021. PMID: 34808377 Review.

2

The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.

Borad MJ, Curtis KK, Babiker HM, Benjamin M, Tibes R, Ramanathan RK, Wright K, Dueck AC, Jameson G, Von Hoff DD. Borad MJ, et al. J Cancer. 2012;3:345-53. doi: 10.7150/jca.4714. Epub 2012 Aug 17. J Cancer. 2012. PMID: 22962561 Free PMC article.

3

A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.

Borad MJ, Babiker HM, Anthony S, Mita M, Buchbinder A, Keilani T, Grem J. Borad MJ, et al. Cancer Invest. 2015 May;33(5):172-9. doi: 10.3109/07357907.2015.1019677. Epub 2015 Apr 6. Cancer Invest. 2015. PMID: 25844818 Clinical Trial.

4

Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas.

Elquza E, Babiker HM, Howell KJ, Kovoor AI, Brown TD, Patel H, Malangone SA, Borad MJ, Dragovich T. Elquza E, et al. Among authors: babiker hm. Cancer Invest. 2016;34(2):57-63. doi: 10.3109/07357907.2015.1108426. Epub 2016 Jan 25. Cancer Invest. 2016. PMID: 26810581 Clinical Trial.

5

Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma.

Babiker HM, Riaz IB, Shah SR, Von Hoff DD, Borad MJ. Babiker HM, et al. Anticancer Drugs. 2017 Feb;28(2):127-132. doi: 10.1097/CAD.0000000000000437. Anticancer Drugs. 2017. PMID: 27685167 Review.

6

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.

Babiker HM, Riaz IB, Husnain M, Borad MJ. Babiker HM, et al. Oncolytic Virother. 2017 Feb 9;6:11-18. doi: 10.2147/OV.S100072. eCollection 2017. Oncolytic Virother. 2017. PMID: 28224120 Free PMC article. Review.

7

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment.

Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Mun EJ, et al. Clin Cancer Res. 2018 Jan 15;24(2):266-275. doi: 10.1158/1078-0432.CCR-17-1117. Epub 2017 Aug 1. Clin Cancer Res. 2018. PMID: 28765323 Review.

8

Exploring the role of oncolytic viruses in hepatobiliary cancers.

Tenneti P, Borad MJ, Babiker HM. Tenneti P, et al. Immunotherapy. 2018 Aug;10(11):971-986. doi: 10.2217/imt-2018-0048. Epub 2018 Jun 14. Immunotherapy. 2018. PMID: 29900755

9

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.

Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS. Babiker HM, et al. Invest New Drugs. 2019 Aug;37(4):636-645. doi: 10.1007/s10637-018-0668-8. Epub 2018 Sep 28. Invest New Drugs. 2019. PMID: 30264293 Free PMC article. Clinical Trial.

10

Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).

Chandana S, Babiker HM, Mahadevan D. Chandana S, et al. Expert Opin Investig Drugs. 2019 Feb;28(2):161-177. doi: 10.1080/13543784.2019.1557145. Epub 2018 Dec 16. Expert Opin Investig Drugs. 2019. PMID: 30539678 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page